

## Practical Gynecology, 2nd Edition – Chapter 4 8 References

1. **Chantigian PDM.** Vaginitis: a common malady. *Prim Care.* 1988;15:517.
- \*2. **Centers for Disease Control and Prevention.** 2006 Guidelines for treatment of sexually transmitted diseases. *MMWR.* 2006;55(No. RR-11):1-94. *This detailed document summarizes the most recent CDC guidelines for the treatment of vaginitis and sexually transmitted diseases (STDs). It also provides an eloquent review of the clinical aspects of these diseases.*
3. **Marrazzo JM, Koutsky LA, Eschenbach DA, Agnew K, Stine K, Hillier SL.** Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. *J Infect Dis.* 2002;185(9):1307-1313.
- \*4. **Myer L, Kuhn L, Stein ZA, Wright TC JR., Denny L.** Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. *Lancet Infect Dis.* 2005;(12):786-794.
- \*5. **Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK.** Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. *Am J Med.* 1983;74:14 –22.
6. **Hill LV.** Anaerobes and *Gardnerella vaginalis* in non-specific vaginitis. *Genitourin Med.* 1985;61:114-9.
- \*7. **McDonald H, Brocklehurst P, Gordon A.** Antibiotics for treating bacterial vaginosis in pregnancy. *Cochrane Database Syst Rev.* 2007;(1):CD000262.
8. **Faro S, Martens M Maccato M Hammill H, Pearlman M.** Vaginal flora and pelvic inflammatory disease. *Am J Obstet Gynecol.* 1993;169(2 pt 2):470-474.
- \*9. **Taha ET, Hoover DR, Dallabetta GA, et al.** Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. *AIDS.* 1998;12:1699-1706.
- \*10. **Koumans EH, Kendrick JS.** Preventing adverse sequelae of bacterial vaginosis: public health program and research agenda. *Sex Transm Dis.* 2001;28(5):292-297.
- \*11. **Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK.** High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. *J Infect Dis.* 2006;193:1478-1386.
- \*12. **Sobel JD, Ferris D, Schwebke J, et al.** Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. *Am J Obstet Gynecol.* 2006;194:1283-9.
13. **Moi H, Erkkola R, Jerve F, et al.** Should male consorts of women with bacterial vaginosis be treated? *Genitourin Med.* 1989;65:263-8.

- \*14. **Sobel JD.** Vulvovaginal candidosis. *Lancet.* 2007;369:1961-1971. *Comprehensive and up-to-date summary about the epidemiology, pathogenesis, diagnosis, and treatment of vulvovaginal candidiasis.*
- \*15. **Sobel JD.** Vaginitis. *N Engl J Med.* 1997;26:1896-1903.
16. **Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK.** Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. *Obstet Gynecol.* 1998;92:757-65.
17. **Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS.** Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. *Obstet Gynecol.* 2002;99:419-25.
- \*18. **Sobel JD, Brooker D, Stein GE, et al.** Single oral dose fluconazole compared to conventional topical therapy of *Candida* vaginitis. *Am J Obstet Gynecol.* 1995;172:1263-8.
- \*19. **Nyirjesy P, Sobel JD.** Vulvovaginal candidiasis. *Obstet Gynecol Clin N America.* 2003;30:671-84.
- \*20. **Wiese W, Patel SR, Patel SC, Ohl CA, Estrada CA.** A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. *Am J Med.* 2000;108:301-8.
- \*21. **Klebanoff MA, Carey JC, Hauth JC, Hillier SL, Nugent RP, Thom EA, Ernest JM, Heine RP, Wapner RJ, Trout W, Moawas A, Leveno KJ.** Failure of metronidazole to prevent preterm delivery among women with asymptomatic *Trichomonas vaginalis* infection. *N Eng J Med.* 2001;345:487-493. *This sentinel study changed the way trichomonas vaginalis infection is managed during pregnancy.*
22. **Murphy R.** Desquamative inflammatory vaginitis. *Dermatologic Therapy.* 2004;17:47-49.
- \*23. **Edwards L.** The diagnosis and treatment of infectious vaginitis. *Dermatologic Therapy.* 2004;17:102-110. *This summary reviews the major infectious vaginitides as well as some of the more uncommon ones.*
24. **Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG.** A prospective population-based study of menopausal symptoms. *Obstet Gynecol.* 2000;96:351-358.
25. **Pandit L, Ouslander JG.** Post-menopausal vaginal atrophy and atrophic vaginitis. *Am J Med Sci.* 1997;314:228-31.
- \*26. **Bygdeman M, Swahn ML.** Replens versus dienoestrol cream in symptomatic treatment for vaginal atrophy in postmenopausal women. *Maturitas.* 1996;23:353-7.

- \*27. **Margesson LJ.** Contact dermatitis of the vulva. *Dermatologic Therapy*. 2004;17:20-27. *This is an excellent summary of the etiology, diagnosis, and treatment of the major dermatologic conditions that affect the vulva.*
28. **Fleming DT, Wasserheit JN.** From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. *Sex Transm Infect*. 1999;75:3-17.
- \*29. **Wolner-Hanssen P, Eschenbach DA, Paavonen J, Stevens CE, Kiviat NB, Critchlow C, DeRouen T, Koutsky L, Holmes KK.** Association between vaginal douching and acute pelvic inflammatory disease. *JAMA*. 1990; 263:1936.
30. **Eschenbach DA.** Acute pelvic inflammatory disease: etiology, risk factors, and pathogenesis. *Clin Obstet Gynecol*. 1976;19:147.
- \*31. **Grimes DA.** Intrauterine device and upper-genital-tract infection. *Lancet*. 2000; 356:1013-1019. *This excellent review debunks the myth that contemporary IUDs cause infection or infertility.*
32. **Leone P, Fleming DT, Gilsean AW, Li L, Justus S.** Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. *Sex Transm Dis*. 2004; 3:311-316.
- \*33. **Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE.** Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States *JAMA*. 2006;296(8):964-73.
- \*34. **Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L.** Risk factors for the sexual transmission of genital herpes. *Ann Intern Med*. 1992; 116:197-202.
- \*35. **Wald A.** New therapies and prevention strategies for genital herpes. *Clin Infect Dis*. 1999;28(Suppl 1):S4-13.
- \*36. **Corey L, Wald A, Patel R, Sacks SL, Tyring SK for the Valacyclovir HAS Transmission Group.** Once-daily valacyclovir to reduce risk of transmission of genital herpes. *N Eng J Med*. 2004; 350:11-20. *This well-designed randomized study supports the use of suppression therapy to effectively reduce the risk of transmission of HSV.*
- \*37. **Beutner KR, Wiley DR, Douglas JM, Tyring SK, Fife K, Trofatter K, Stone KM.** Genital warts and their treatment. *Clin Infect Dis*. 1999(Suppl 1);S37-56.
38. **Jablonska S.** Traditional therapies for the treatment of condylomata acuminata (genital warts). *Australas J Dermatol*. 1998;39 (Suppl 1):S2-4.
39. **Mastro TD, de Vincenzi I.** Probabilities of sexual HIV-1 transmission. *AIDS*. 1996;10 (Suppl A):S75-82.
40. **Quinn TC, Wawer MJ, Sewankambo N, et al.** Viral load and heterosexual transmission of human immunodeficiency virus type 1. *N Engl J Med*. 2000;342:921-9.

40a. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings. *MMWR Recomm Rep.* 2006;55(RR-14):1-17.

\*41. **Ting PT, Dytoc MT.** Therapy of external anogenital warts and molluscum contagiosum: a literature review. *Dermatol Therap.* 2004;17:68-101.